Rheumatoid Arthritis KOL Interview – UK

Rheumatoid Arthritis KOL Interview – UK

  • July 2019 •
  • 14 pages •
  • Report ID: 5807898 •
  • Format: PDF
A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.